Ambu faces severe investor backlash post-earnings
Ambu’s latest quarterly report induced a sharp reaction from investors, with the company’s stock dropping over 16% by 2 pm. Despite having revealed overarching sales figures in July, the finalized quarterly report appeared to fall short of expectations regarding the company’s endoscopy business. Søren Løntoft Hansen, senior analyst at Sydbank, suggested that particularly within pulmonary endoscopy, the growth rates were lower than anticipated. With endoscopes making up a majority of the business, this has not been enough to reassure investors. Ambu reported a 15% growth from the same quarter last year with a total revenue of nearly 1.4 billion Danish kroner. Expectations for growth rates in pulmonary endoscopy are exceptionally high, not only for the next year but also for the following three years. The shortfall in expected performance creates uncertainty around the company’s growth foundation, causing investor apprehension. The report confirms an anticipated organic growth of 12 to 14 percent for the entire year.